The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.
(Reuters) -Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine ...
At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting ...
19h
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...
Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals.
There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...
5don MSN
Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration’s top vaccine official was forced to resign, the most high-profile exit at the regulator as the ...
A Durham biotechnology company has seen its stock price plummet over the past few days amid a stock offering and a media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback